Holland & Knight advised EmVenio Research, the largest provider of community-based clinical trial sites served with mobile research units, in its acquisition by PCM Trials. The acquisition, which is effective immediately, was announced on February 23.
With the combination of capabilities with EmVenio, PCM Trials now has access to a site network that is focused on serving underrepresented patient populations in previously hard-to-reach communities and can work flexibly with sponsors to achieve their study goals.
EmVenio, based in Durham, North Carolina, provides rapid and scalable mobile community research site solutions to reach and recruit diverse, underserved and high-risk communities through its 63 mobile sites across 22 U.S. states and 10 locations in the United Kingdom.
Headquartered in Denver, Colorado with a European regional office located in the Netherlands, PCM Trials is the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs).
Holland & Knight Partner Tyler Hand and Associates Jared Adams and Taylor Smith led the corporate team in the firm's representation of EmVenio. They were assisted by Partners James Bristol, Stacy Hooper, Frederick Conrad III and Shane Morris.
More information about the transaction can be found here.
Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG (formerly Refinitiv), Mergermarket, PitchBook and The Deal. In 2023, the firm ranked among the top 5 most active law firms in the U.S. and globally for its work in the space and ranked as the most active law firm in the country for healthcare private equity transactions. Through the HK Deal Flow℠ program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.
Original source can be found here.